許凱程(Hsu, Kai-Cheng) 教授

Email
piki@tmu.edu.tw
現   職
癌症生物學與藥物研發研究所 教授

學經歷

學 歷

畢業學校與學位[修業時間]
國立交通大學生物資訊及系統生物研究所 博士
2007/09~2011/06
國立交通大學生物資訊研究所 碩士
2005/09~2007/07
國立交通大學生物科技學系 學士
2001/09~2005/06

本校學術經歷

任職單位與職稱[起迄時間]
癌症生物學與藥物研發研究所教授
2022/08/01~
癌症生物學與藥物研發研究所副教授
2019/02/01~2022/07/31
癌症生物學與藥物研發研究所助理教授
2018/12/01~2019/01/31
癌症生物學與藥物研發博士學位學程助理教授
2015/11/05~2018/11/30

本校兼職教學行政經歷

服務單位與職稱[起迄時間]
臨床基因體學暨蛋白質體學碩士學位學程副教授
2021/11/01 ~
國際轉譯科學博士學位學程副教授
2021/07/01 ~
(舊)生技醫療產業研發博士學位學程副教授
2019/11/01 ~
癌症生物學與藥物研發博士學位學程助理教授
2019/01/01 ~

其它經歷

任職單位與職稱[起迄時間]
國立交通大學約聘助理研究員
2013/08/01~2015/11/04
國立交通大學博士後研究員
2011/09/29~2013/07/31

專長與研究領域

學門領域
生物學之生化及分子生物
生物資訊與醫療資訊
學術專長

論文著作

清冊下載


1. 2024 Wu YW,HuangFu WC,Lin TE,Peng CH,Tu HJ,Sung TY, Sung TY, Yen SC, Pan SL, Hsu KC. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule . International Journal of Biological Macromolecules .2024

2. 2024 Lin TE,Dyan Y,HuangFu WC,Wu YW,Hsu JY,Yen SC, Sung TY, Hsieh JH, Pan SL, Yang CR, Huang WJ, Hsu KC. An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors . Protein Science .2024

3. 2024 Huang CC,Hsu CM,Chao MW,Hsu KC,Lin TE,Yen SC, Tu HJ, Pan SL. In silico Identification of a Novel Cdc2-like kinase 2 (CLK2) Inhibitor in Triple Negative Breast Cancer . Protein Science .2024

4. 2023 Lien ST,Lin TE,Hsieh JH,Sung TY,Che JH,Hsu KC. Establishment of extensive artificial intelligence models for kinase inhibitor prediction: identification of novel PDGFRB inhibitors . Computers in Biology and Medicine .2023

5. 2023 Chin HK,Lu MC,Hsu KC,El-Shazly M,Tsai TN,Lin TY, Shih SP, Lin TE, Wen ZH, Yang YSH, Liu YC. . Exploration of anti-leukemic effect of soft coral-derived 13-acetoxysarcocrassolide: Induction of apoptosis via oxidative stress as a potent inhibitor of heat shock protein 90 and topoisomerase II . Kaohsiung Journal of Medical Sciences .2023

6. 2023 Ho TY,Sung TY,Pan SL,Huang WJ,Hsu KC,Hsu JY, Lin TE, Hsu CM, Yang CR.. The study of a novel CDK8 inhibitor E966-0530-45418 that inhibits prostate cancer metastasis in vitro and in vivo . Biomedicine & Pharmacotherapy .2023

7. 2023 Lu KJ,Chang CW,Wang CH,Chen FY,Huang IY,Huang PH, Yang CH, Wu HY, Wu WJ, Hsu KC, Ho MC, Tsai MD, Liao JC. An ATP-sensitive phosphoketolase regulates carbon fixation in cyanobacteria . Nature Metabolism .2023

8. 2023 Tu HJ,Su CJ,Peng CS,Lin TE,HuangFu WC,Hsu KC, Hwang TL, Pan SL. Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity . Journal of Food and Drug Analysis .2023

9. 2023 Chang YJ,Le UNP,Liu JJ,Li SR,Chao ST,Lai HC, Lin YF, Hsu KC, Lu CH, Lin CW. Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV . Antiviral Research .2023

10. 2023 Chu JC,Tseng HJ,Lee SB,Hsu KC,Hsin LW,Liang RH, Lin TE, Gao NC, Chen LC, Lu WH, Wang AHJ, Huang WJ. Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities . Journal of Enzyme Inhibition and Medicinal Chemistry .2023

11. 2023 Tseng HJ,Banerjee S,Qian B,Lai MJ,Wu TY,Hsu TI, Lin TE, Hsu KC, Chuang KH, Liou JP, Shih JC. Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma . European Journal of Medicinal Chemistry .2023

12. 2023 Lee S,Chao MW,Wu YW,Hsu CM,Lin TE,Hsu KC, Pan SL, Lee HY. Synthesis and evaluation of potent (iso)ellipticine-based inhibitors of MYLK4 accessed via expeditious synthesis from isoquinolin-5-ol . Rsc Advances .2023

13. 2023 Chang CD,Chao MW,Lee HY,Liu YT,Tu HJ,Lien ST, Lin TE, Sung TY, Yen SC, Huang SH, Hsu KC, Pan SL. In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer . Journal of Enzyme Inhibition and Medicinal Chemistry .2023

14. 2023 Hsu JY,Hsu KC,Sun C,Chou CH,Lin TE,Sung TY, Tseng HJ, Yen SC, Yang CR, Huang WJ. Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors . Biomedicine & Pharmacotherapy .2023

15. 2022 Lin LC,Chang HY,Lin TE,Lin JR,Hsia SM,Hsu KC, Huang TC.. Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors . Biomedicine & Pharmacotherapy .2022

16. 2022 Yen SC,Chen LC,Huang HL,HuangFu WC,Chen YY,Lin TE, Lien ST, Tseng HJ, Sung TY, Hsieh JH, Huang WJ, Pan SL, Hsu KC. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach . Bioorganic Chemistry .2022

17. 2022 Yen SC,Wu YW,Huang CC,Chao MW,Tu HJ,Chen CC, Lin TE, Sung TY, Tseng HJ, Chu JC, Huang WJ, Yang CR, HuangFu WC, Pan SL, Hsu KC. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia Phytomedicine . Phytomedicine .2022

18. 2022 Lin TE,Chao MW,HuangFu WC,Tu HJ,Peng ZX,Su CJ, Sung TY, Hsieh JH, Lee CC, Yang CR, Pan SL, Hsu KC. Identification and Analysis of a Selective DYRK1A Inhibitor . Biomedicine & Pharmacotherapy .2022 ;(146):112580

19. 2022 Lu CH,Chung WM,Tsai CH,Cheng JC,Hsu KC,Tzeng HE. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction . Scientific Reports .2022

20. 2022 Lin TE,Sung LC,Chao MW,Li Min,Zheng JH,Sung TY, Hsieh JH, Yang CR, Lee HY, Cho EC, Hsu KC. Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors . Journal of Enzyme Inhibition and Medicinal Chemistry .2022

21. 2022 Lin TE,Yang CR,Chou CH,Hsu JY,Chao MW,Sung TY, Hsieh JH, Huang WJ, Hsu KC. Discovery of a novel cyclin-dependent kinase 8 inhibitor with an oxindole core for anti-inflammatory treatment . Biomedicine & Pharmacotherapy .2022 ;(146):112459

22. 2022 Maestre-Reyna M,Yang CH,Nango E,Huang WC,Putu EPGN,Wu WJ, Wang PH, Franz-Badur S, Saft M, Emmerich HJ, Wu HY, Lee CC, Huang KF, Chang YK, Liao JH, Weng JH, Gad W, Chang CW, Pang AH, Sugahara M, Owada S, Hosokawa Y, Joti Y, Yamashita A, Tanaka R, Tanaka T, Luo FJ, Tono K, Hsu KC, Kiontke S, Schapiro I, Spadaccini R, Royant A, Yamamoto J, Iwata S, Essen LO, Bessho Y, Tsai MD.. Serial crystallography captures dynamic control of sequential electron and proton transfer events in a flavoenzyme . Nature Chemistry .2022

23. 2021 Wang KC,Lu MC,Hsu KC,El-Shazly M,Shih SP,Lien ST,Kuo FW,Yang SC,Chen CL,Yang YCSH. The antileukemic effect of xestoquinone, a marine-derived polycyclic quinone-type metabolite, is mediated through ros-induced inhibition of hsp-90 . Molecules .2021 ;(26)

24. 2021 Fan YC,Hsu KC,Lin TE,Zechner D,Hsu SP,Tsai YC. Investigation of anti-tumor effects of an MLK1 inhibitor in prostate and pancreatic cancers . Biology .2021 ;(10)

25. 2021 Chang CH,Wu S,Hsu KC,Huang WJ,Chen JJ. Dibenzofuran, 4-chromanone, acetophenone, and dithiecine derivatives: Cytotoxic constituents from eupatorium fortunei . International Journal of Molecular Sciences .2021 ;(22)

26. 2021 Chao MW,Lin TE,HuangFu WC,Chang CD,Tu HJ,Chen LC,Yen SC,Sung TY,Huang WJ,Yang CR,Pan SL,Hsu KC. Identification of a Dual TAOK1 and MAP4K5 Inhibitor Using a Structure-Based Virtual Screening Approach . Journal of Enzyme Inhibition and Medicinal Chemistry .2021

27. 2021 Huang KW,Chen JW,Hua TY,Chu YY,Chiu TY,Liu JY, Tu CI, Hsu KC, Kao YT, Chu JW, Hsiao YY. Targeted Covalent Inhibitors Allosterically Deactivate the DEDDh Lassa Fever Virus NP Exonuclease from Alternative Distal Sites . JACS Au .2021 ;(1):2315-2327

28. 2021 Ojha R,Chen IC,Hsieh CM,Nepali K,Lai RW,Hsu KC, Lin TE, Pan SL, Chen MC, Liou JP. Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent . Journal of Medicinal Chemistry .2021

29. 2021 Yen SC,Chen LC,Huang HL,Ngo ST,Wu YW,Lin TE,Sung TY,Lien ST,Tseng HJ,Pan SL,Huang WJ,Hsu KC. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia . Journal of Natural Products .2021

30. 2021 Chang TY,Nepali K,Chen YY,Yang YCSH,Hsu KC,Yen Y,Pan SL,Liou JP,Lee SB. A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling . Biomedicine and Pharmacotherapy .2021 ;(138)

31. 2021 Hsu JY,Rao Sathyan A,Hsu KC,Chen LC,Yen CC,Tseng HJ, Wu KC, Liu HK, Huang WJ. Synthesis of yakuchinone b-inspired inhibitors against islet amyloid polypeptide aggregation . Journal of Natural Products .2021 ;(84):1096-1103

32. 2021 Nepali K,Hsu TI,Hsieh CM,Lo WL,Lai MJ,Hsu KC, Lin TE, Chuang JY, Liou JP. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma . European Journal of Medicinal Chemistry .2021 ;(217)

33. 2021 Huang KF,Huang JS,Wu ML,Hsieh WL,Hsu KC,Hsu HL, Ko TP, Wang AH. A Unique Carboxylic-Acid Hydrogen-Bond Network (CAHBN) Confers Glutaminyl Cyclase Activity on M28 Family Enzymes . Journal of Molecular Biology .2021

34. 2021 Wang SA,Young MJ,Wang YC,Chen SH,Liu CY,Lo YA, Jen HH, Hsu KC, Hung JJ. USP24 promotes drug resistance during cancer therapy . Cell Death and Differentiation .2021

35. 2021 Chang YJ,Yeh CY,Cheng JC,Huang YQ,Hsu KC,Lin YF, Lu CH. Potent sialic acid inhibitors that target influenza A virus hemagglutinin . Scientific Reports .2021

36. 2021 Wu YW,Chao MW,Tu HJ,Chen LC,Hsu KC,Liou JP, Yang CR, Yen SC, HuangFu WC, Pan SL. A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo . Oncogenesis .2021

37. 2021 Hsu KC,Chu JC,Tseng HJ,Liu CI,Wang HC,Lin TE, Lee HS, Hsin LW, Wang AH, Lin CH, Huang WJ.. Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors . European Journal of Medicinal Chemistry .2021

38. 2021 Singh A,Chang TY,Kaur N,Hsu KC,Yen Y,Lin TE, Lai MJ, Lee SB, Liou JP. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition . European Journal of Medicinal Chemistry .2021

39. 2020 Ojha R,Nepali K,Chen CH,Chuang KH, Wu TY,Lin TE,Hsu KC,Chao MW,Lai MJ,Lin MH,Huang HL,Chang CD,Pan SL,Chen MC,Liou JP. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo . European Journal of Medicinal Chemistry .2020 ;(190):112086

40. 2020 Kang CY,Huang IH,Chou CC,Wu TY,Chang JC,Hsiao YY,Cheng CH,Tsai WJ,Hsu KC,Wang S. Functional analysis of Clostridium difficile sortase B reveals key residues for catalytic activity and substrate specificity . Journal of Biological Chemistry .2020 ;(295):3734-3745

41. 2020 Hsu MH,Hsieh CY,Kapoor M,Chang JH,Chu HL,Cheng TM,Hsu KC,Lin TE,Tsai FY,Horng JC. Leucettamine B analogs and their carborane derivative as potential anti-cancer agents: Design, synthesis, and biological evaluation . Bioorganic Chemistry .2020 ;(98):103729

42. 2020 Tseng HJ,Lin MH,Shiao YJ,Yang YC,Chu JC,Chen CY,Chen YY,Lin TE,Su CJ,Pan SL,Chen LC,Wang CY,Hsu KC,Huang WJ. Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease . European Journal of Medicinal Chemistry, .2020 ;(192):112193

43. 2020 Lin CF,Hsu KC,Huangfu WC,Lin TE,Huang LI,Pan SL. Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury . BMC Pharmacology & Toxicology .2020 ;(21):21-21

44. 2020 Nepali K,Chang TY,Lai MJ,Hsu KC,Yen Y, Lin TE,Lee SB,Liou JP. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors . European Journal of Medicinal Chemistry .2020 ;(196)

45. 2020 Liao YT,Lin SJ,Ko TP,Liu CY,Hsu KC,Wang HC. Structural insight into the differential interactions between the DNA mimic protein SAUGI and two gamma herpesvirus uracil-DNA glycosylases . International Journal of Biological Macromolecules .2020 ;(160):903-914

46. 2020 Liu YC,Peng BR,Hsu KC,El-Shazly M,Shih SP,Lin TE,Kuo FW,Chou YC,Lin HY,Lu MC. 13-acetoxysarcocrassolide exhibits cytotoxic activity against oral cancer cells through the interruption of the keap1/Nrf2/p62/SQSTM1 pathway: The need to move beyond classical concepts . Marine Drugs .2020 ;(18)

47. 2020 Hsu KC,HuangFu WC,Lin TE,Chao MW,Sung TY,Chen YY,Pan SL,Lee JC,Tzou SC,Sun CM,Yang JM. A site-moiety map and virtual screening approach for discovery of novel 5-LOX inhibitors . Scientific Reports .2020 ;(10)

48. 2020 Chen LC,Huang HL,HuangFu WC,Yen SC,Ngo ST,Wu YW,Lin TE,Sung TY,Lien ST,Tseng HJ,Pan SL,Huang WJ,Hsu KC. Biological Evaluation of Selected Flavonoids as Inhibitors of MNKs Targeting Acute Myeloid Leukemia . Journal of Natural Products .2020

49. 2020 Wu WC,Liu YM,Liao YH,Hsu KC,Lien ST,Chen IC,Lai MJ,Li YH,Pan SL,Chen MC,Liou JP. Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells . European Journal of Medicinal Chemistry .2020 ;(203)

50. 2020 Chou CH,Hsu KC,Lin TE,Yang CR. Anti-inflammatory and tau phosphorylation–inhibitory effects of eupatin . Molecules .2020 ;(25):5652

51. 2020 Magnolol, A Novel Antagonist of Thrombin and PAR-1, Inhibits Thrombin-Induced Connective Tissue Growth Factor (CTGF) Expression in Vascular Smooth Muscle Cells and Ameliorate Pathogenesis of Restenosis in Rats . Applied Sciences .2020

52. 2019 Lai MJ,Ojha R,Lin MH,Lee HY,Lin TE,Hsu KC, Chang CY, ChenMC, Nepali K, Chang JY, Liou JP. 1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase . European journal of medicinal chemistry .2019 ;(162):612-630

53. 2019 New paradigm of functional regulation by DNA mimic proteins: Recent updates . Iubmb Life .2019 ;(71):539-548

54. 2019 Structural Insights to the Heterotetrameric Interaction between the Vibrio parahaemolyticus PirAvp and PirBvp Toxins and Activation of the Cry-Like Pore-Forming Domain . Toxins .2019 ;(11):233

55. 2019 Young MJ,Hsu KC,Lin TE,Chang WC,Hung JJ. The role of ubiquitin-specific peptidases in cancer progression . Journal of Biomedical Science .2019 ;(26):42

56. 2019 Lee CC,Chang WH,Chang YS,Yang JM,Chang CS,Hsu KC,Chen YT,Liu TY,Chen YC,Lin Y,Wu YC,Chang JG. Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5-diamino-6-chloro-N-(N-(2,6-dichlorobenzoyl)carbamimidoyl)pyrazine-2-carboxide . Molecular Oncology .2019 ;(13):1744-1762

57. 2019 NN,Lin MH,Chao MW,Peng SJ,Hsu KC,Lin TE,Chen MC,Lai MJ,Pan SL,Liou JP. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells . Bioorganic Chemistry .2019 ;(91):103119

58. 2019 Yang PM,Hong YH,Hsu KC,Liu TP . p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma . American Journal of Cancer Research .2019 ;(9):2120-2139

59. 2019 Lin CH,Lee HH,Kuei CH,Lin HY,Lu LS,Lee FP,Chang J,Wang JY,Hsu KC,Lin YF. Nicotinic Acetylcholine Receptor Subunit Alpha-5 Promotes Radioresistance via Recruiting E2F Activity in Oral Squamous Cell Carcinoma . Journal of Clinical Medicine .2019 ;(8):1454

60. 2018 Wu YW,Hsu KC ,Lee HY,Huang TC,Lin TE,Chen YL, Sung TY, Liou JP, Hwang-Verslues WW, Pan SL, HuangFu WC. A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability . Frontiers in Pharmacology .2018 ;(9):205

61. 2018 Yeh KT, Hsu KC, Hsu NY, Cheng YW. miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation . Oncology Letters .2018 ;(15):8107

62. 2018 Lee HY,Fan SJ,Huang FI,Chao HY,Hsu KC,Lin TE, Yeh TK, Lai MJ, Li YH, Huang HL, Yang CR, Liou JP. 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes . Journal of Medicinal Chemistry .2018 ;(61):7087-7102

63. 2018 Chen LC ,Tseng HJ,Liu CY,Huang YY,Yen CC,Weng JR, Lu YL, Hou WC, Lin TE, Pan IH, Huang KK, Huang WJ, Hsu KC. Design of Diarylheptanoid Derivatives as Dual Inhibitors Against Class IIa Histone Deacetylase and beta-amyloid Aggregation . Frontiers in Pharmacology .2018 ;(9):708

64. 2018 Lin TE,HuangFu WC,Chao MW,Sung TY,Chang CD,Chen YY,Hsieh JH,Tu HJ,Huang HL,Pan SL,Hsu KC. A novel selective JAK2 inhibitor identified using pharmacological interactions . Frontiers in Pharmacology .2018 ;(9):1379

65. 2018 Chao SW,Chen LC,Yu CC,Liu CY,Lin TE,Guh JH, Wang CY, Chen CY, Hsu KC, Huang WJ. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities . European Journal of Medicinal Chemistry .2018 ;(143):792-805

66. 2017 Huang MF,Lin SJ,Ko TP,Liao YT,Hsu KC,Wang HC. The monomeric form of Neisseria DNA mimic protein DMP19 prevents DNA from binding to the histone-like HU protein . PLoS One 2017 .2017 ;(12):e0189461

67. 2017 Hsu KC,Hung HC,HuangFu WC,Sung TY,Eight Lin T,Fang MY, Chen IJ, Pathak N, Hsu JT, Yang JM. Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains . Scientific Reports. .2017 ;(7):12336

68. 2017 Chen LC,Hsu KC,Chiou LC,Tseng HJ,Huang WJ. Total Synthesis and Metabolic Stability of Hispidulin and Its d-Labelled Derivative . Molecules .2017 ;(22)

69. 2017 Lin SJ,Hsu KC,Wang HC. Structural Insights into the Cytotoxic Mechanism of Vibrio parahaemolyticus PirAvp and PirBvp Toxins . Marine Drugs .2017 ;(15):373

70. 2017 Chen CH,Changou C ,Hsieh TH,Lee YC,Chu CY,Hsu KC, Wang HC, Lin YC, Lo YN, Liu YR, Liou J P, Yen Y. Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer . Clinical Cancer Research .2017

71. 2017 Chao MW,Huang HL,HuangFu WC,Hsu KC,Liu YM,Wu YW, Lin CF, Chen YL, Lai MJ, Lee HY, Liou JP, Teng CM, Yang CR. An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells . Oncotarget .2017

72. 2017 Hsu KC,Liu CY,Lin TE,Hsieh JH,Sung TY,Tseng HJ, Yang JM, Huang WJ. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach. . Scientific reports .2017 ;(7):3228

73. 2016 Lin CH,Wu YR,Yang JM,Chen WL,Chao CY,Chen IC, Lin TH, Wu YC, Hsu KC, Chen CM, Lee GC, Hsieh-Li HM, Lee CM, Lee-Chen GJ. Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3 . Cns & Neurological Disorders-Drug Targets .2016 ;(15):351-359

74. 2016 Wang HC,Ho CH,Chou CC,Ko TP,Huang MF,Hsu KC, Wang AHJ. Using structural-based protein engineering to modulate the differential inhibition effects of SAUGI on human and HSV uracil DNA glycosylase . Nucleic Acids Research .2016 ;(44):4440-4449

75. 2016 Chung YL,Pan CH,Wang CCN,Hsu KC,Sheu MJ,Chen HF, Wu CH. Methyl Protodioscin, a Steroidal Saponin, Inhibits Neointima Formation in Vitro and in Vivo . Journal of Natural Products .2016 ;(79):1635-1644

76. 2016 Das A,Adak AK,Ponnapalli K,Lin CH,Hsu KC,Yang JM, Hsu TA, Lin CC. Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors . European Journal of Medicinal Chemistry .2016 ;(123):397-406

77. 2016 Huang KW,Hsu KC,Chu LY,Yang JM,,Yuan HS,Hsiao YY. Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate . Journal of Medicinal Chemistry .2016 ;(59):8019-8029

78. 2015 Hsu KC,Sung TY,Lin CT,Chiu YY,Hsu JTA,Hung HC, Sun CM, Barve I, Chen WL, Huang WC, Huang CT, Chen CH, Yang JM. Anchor-based classification and type-C inhibitors for tyrosine kinases . Scientific Reports .2015 ;(5):10938-10951

79. 2015 Lee GC,Lin CH,Tao YC,Yang JM,Hsu KC,Huang YJ, Huang SH, Kung PJ, Chen WL, Wang CM, Wu YR, Chen CM, Lin JY, Hsieh-Li HM, Lee-Chen GJ. The potential of lactulose and melibiose, two novel trehalase-indigestible and autophagy-inducing disaccharides, for polyQ-mediated neurodegenerative disease treatment . Neurotoxicology .2015 ;(48):120

80. 2014 Chiu YY,Tseng JH,Liu KH,Lin CT,Hsu KC,Yang JM. Homopharma: A new concept for exploring the molecular binding mechanisms and drug repurposing . Bmc Genomics .2014 ;(15 Sup):S8

81. 2014 Lee CC,Maestre-Reyna M,Hsu KC,Wang HC,Liu CI,Jeng WY, Lin LL, Wood R, Chou CC, Yang JM, Wang AHJ. Crowning Proteins: Modulating the Protein Surface Properties using Crown Ethers . Angewandte Chemie-International Edition .2014 ;(53):13054

82. 2014 Ma NH,Lai CS,Chung CH,Yang JM,Hsu KC,Hsu KC, Chen CY, Chung TS, Li SM, Ho CT, Pan MH. 5-Demethyltangeretin is more potent than tangeretin in inhibiting dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumorigenesis. . Journal of Functional Foods .2014 ;(11):528

83. 2014 Chu CH,Wang LY,Hsu KC,Chen CC,Cheng HH,Wang SM, Wu CM, Chen TJ, Li LT, Liu RW, Hung CL, Yang JM, Kung HJ, Wang WC. KDM4B as a Target for Prostate Cancer: Structural Analysis and Selective Inhibition by a Novel Inhibitor . Journal of Medicinal Chemistry .2014 ;(57):5975

84. 2014 Wang HC,Ho CH,Hsu KC,Yang JM,Wang AHJ. DNA Mimic Proteins: Functions, Structures, and Bioinformatic Analysis . Biochemistry .2014 ;(53):2865

85. 2014 Wang HC,Hsu KC,Yang JM,Wu ML,Ko TP,Lin SR, Wang AHJ. Staphylococcus aureus protein SAUGI acts as a uracil-DNA glycosylase inhibitor . Nucleic Acids Research .2014 ;(42):1354

86. 2013 Hsu KC,Cheng WC,Chen YF,Wang WC,Yang JM. Pathway-based Screening Strategy for Multitarget Inhibitors of Diverse Proteins in Metabolic Pathways. . Plos Computational Biology .2013 ;(9):e10031

87. 2013 Lin CH,Chang TC,Das A,Fang MY,Hung HC,Hsu KC, Yang JM, von Itzstein M, Mong KKT, Hsu TA, Lin CC. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities . Organic & Biomolecular Chemistry .2013 ;(11):3943

88. 2013 Hsu KC,Hung HC,Horng JT,Fang MY,Chang CY,Li LT, Chen IJ, Chen YC, Chou DL, Chang CW, Hsieh HP, Yang JM, Hsu JTA. Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors . PLoS One .2013 ;(8):e56704

89. 2013 Chiu YY,Lin CT,Huang JW,Hsu KC,Tseng JH,You SR, Yang JM. KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms . Nucleic Acids Research .2013 ;(41):D430

90. 2012 Cheng WC,Chen YF,Wang HJ,Hsu KC,Lin SC,Chen TJ, Yang JM, Wang WC. Structures of Helicobacter pylori Shikimate Kinase Reveal a Selective Inhibitor-Induced-Fit Mechanism . Plos One .2012 ;(7):e33481

91. 2012 Hsu KC,Cheng WC,Chen YF,Wang HJ,Li LT,Wang WC, Yang JM. Core Site-Moiety Maps Reveal Inhibitors and Binding Mechanisms of Orthologous Proteins by Screening Compound Libraries. . PLoS One .2012 ;(7):e32142

92. 2012 Hsu KC,Chen YF,Yang JM. GemAffinity: a scoring function for predicting binding affinity and Virtual Screening . International Journal of Data Mining and Bioinformatics .2012 ;(6):27

93. 2012 Chiu YY,Lin CY,Lin CT,Hsu KC,Chang LZ,Yang JM. Space-related pharma-motifs for fast search of protein binding motifs and polypharmacological targets . BMC Genomics .2012 ;(13Sup7):S21

94. 2011 Clinciu DL,Yang JM,Hsu KC,Lo CC,Wallace S,Yu HC. The Relevance of Protein-Ligand Interaction Profiles in Computer-Aided Novel Compound Design and Applications . Current Bioinformatics .2011 ;(6):383

95. 2011 Tsai CC,Liu HF,Hsu KC,Yang JM,Chen CP,Liu KK, Hsu TS, Chao JI. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration . Biochemical Pharmacology .2011 ;(81):856

96. 2011 Hsu KC,Chen YF,Lin SR,Yang JM. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis . Bmc Bioinformatics .2011 ;(12Sup1):S33

97. 2010 Chen YF,Hsu KC,Lin SR,Wang WC,Huang YC,Yang JM. SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties . Nucleic Acids Research .2010 ;(38):W424

98. 2010 Liu KP,Hsu KC,Huang JW,Chang LS,Yang JM. ATRIPPI: An Atom-Residue Preference Scoring Function for Protein-Protein Interactions . International Journal on Artificial Intelligence Tools .2010 ;(19):251

研究計畫

計畫名稱
113 設計與優化新穎蛋白質激酶抑制劑應用於胰臟癌之療效與機轉探討(3/3)
補助單位
國家科學及技術委員會

計畫名稱
113 研發新穎性標的 RNA splicing 抑制劑用於治療消化道癌症之智慧型藥物設計與轉譯研究-利用人工智慧與以結構為基礎策略設計與優化新穎DYRK1/CLK抑制劑(2/3)
補助單位
國家科學及技術委員會

計畫名稱
113 「設計與優化新穎蛋白質激酶抑制劑應用於胰臟癌之療效與機轉探討」-吳逸玟君
補助單位
國家科學及技術委員會

計畫名稱
112 建立人工智慧模型預測新穎性TBK1抑制 劑與探討其抗發炎機轉
補助單位
國家科學及技術委員會

計畫名稱
112 新穎抑制劑篩選研究計畫
補助單位
圖策科技股份有限公司

計畫名稱
112 小分子結合位相之預測與分析
補助單位
財團法人生物技術開發中心

計畫名稱
112 設計與優化新穎蛋白質激酶抑制劑應用於胰臟癌之療效與機轉探討(2/3)
補助單位
國家科學及技術委員會

計畫名稱
112 研發新穎性標的 RNA splicing 抑制劑用於治療消化道癌症之智慧型藥物設計與轉譯研究-利用人工智慧與以結構為基礎策略設計與優化新穎DYRK1/CLK抑制劑(1/3)
補助單位
國家科學及技術委員會

計畫名稱
112 貴校延攬吳逸玟君參與「設計與優化新穎蛋白質激酶抑制劑應用於胰臟癌之療效與機轉探討」
補助單位
國家科學及技術委員會

計畫名稱
112 「補助國內研究生出席國際學術會議」9th RSC-BMCS Fragment-based Drug Discovery meeting。(研究生:癌症生物學與藥物研發博士學位學程博士班林偉德君)
補助單位
國家科學及技術委員會

計畫名稱
111 設計與優化新穎蛋白質激酶抑制劑應用於胰臟癌之療效與機轉探討(1/3)
補助單位
國家科學及技術委員會

計畫名稱
111 111年度【產學合作計畫-人工智能技術應用於新穎胰臟癌藥物研發與優化(2/2)】
補助單位
國家科學及技術委員會

計畫名稱
111 111年度【產學合作計畫-人工智能技術應用於新穎胰臟癌藥物研發與優化(2/2)】
補助單位
安邦生技股份有限公司

計畫名稱
111 設計與優化新穎蛋白質激酶抑制劑應用於胰臟癌之療效與機轉探討-吳逸玟
補助單位
國家科學及技術委員會

計畫名稱
111 日本藥學會 第143年會(研究生:癌症生物學與藥物研發博士學位學程博士班徐瑞怡君)
補助單位
國家科學及技術委員會

計畫名稱
110 開發新穎TBK1抑制劑並評估其抑制胰臟癌的功效與探討機轉
補助單位
國家科學及技術委員會

計畫名稱
110 建立以結構為基礎之藥物篩選模型並應用於研發新穎性蛋白激酶抑制劑
補助單位
國家科學及技術委員會

計畫名稱
110 電腦輔助篩選激酶抑制劑
補助單位
財團法人工業技術研究院

計畫名稱
110 針對癌症治療研發與活性最適化蛋白質激酶抑制劑(3/3)
補助單位
科技部

計畫名稱
110 人工智能技術應用於新穎胰臟癌藥物研發與優化(1/2)
補助單位
國家科學及技術委員會

計畫名稱
110 人工智能技術應用於新穎胰臟癌藥物研發與優化(1/2)
補助單位
安邦生技股份有限公司

計畫名稱
109 探討pan-HDACs 抑制劑對抗藥性腦癌的抑制療效和作用機轉
補助單位
科技部

計畫名稱
109 預測化合物與蛋白質結合位相研究計畫
補助單位
瑞安商貿有限公司

計畫名稱
109 電腦輔助藥物設計研究計畫
補助單位
光騰新藥股份有限公司

計畫名稱
109 電腦輔助篩選激酶抑制劑
補助單位
財團法人工業技術研究院

計畫名稱
109 針對癌症治療研發與活性最適化蛋白質激酶抑制劑(2/3)
補助單位
科技部

計畫名稱
108 建立新興環境汙染物與藥物毒理預測平台之研究
補助單位
科技部

計畫名稱
108 藉由全方位探索新致病機制發現新的第2型糖尿病之肝臟治療靶點:基於慢性C型肝炎病毒感染模式到一般族群、連結基礎,生物信息學和臨床的系統性探討之轉譯研究-整合生物資訊方法研究C型肝炎誘發之第二型糖尿病的機轉與藥物開發(3/3)
補助單位
科技部

計畫名稱
108 針對癌症治療研發與活性最適化蛋白質激?抑制劑(1/3)
補助單位
科技部

計畫名稱
107 藉由全方位探索新致病機制發現新的第2型糖尿病之肝臟治療靶點:基於慢性C型肝炎病毒感染模式到一般族群、連結基礎,生物信息學和臨床的系統性探討之轉譯研究-整合生物資訊方法研究C型肝炎誘發之第二型糖尿病的機轉與藥物開發(2/3)
補助單位
科技部

計畫名稱
107 研發與設計蛋白質激?抑制劑應用於癌症之治療
補助單位
科技部

計畫名稱
106 研發選擇性非異羥肟酸組蛋白去乙醯酶 4抑制劑
補助單位
科技部

計畫名稱
106 藥物開發研究計畫
補助單位
台灣神隆股份有限公司

計畫名稱
106 藉由全方位探索新致病機制發現新的第2型糖尿病之肝臟治療靶點:基於慢性C型肝炎病毒感染模式到一般族群、連結基礎,生物信息學和臨床的系統性探討之轉譯研究-整合生物資訊方法研究C型肝炎誘發之第二型糖尿病的機轉與藥物開發(1/3)
補助單位
科技部

計畫名稱
106 針對致癌蛋白質激?開發新穎選擇性抑制劑
補助單位
科技部

計畫名稱
105 藥物開發研究計畫
補助單位
台灣神隆股份有限公司

計畫名稱
104 藥物開發
補助單位
台灣神隆股份有限公司

計畫名稱
104 以同藥理蛋白質開發大腸直腸癌多標靶抑制劑
補助單位
科技部

計畫名稱
104 新聘教師研究補助
補助單位
臺北醫學大學